Compare · LSTA vs PCSA
LSTA vs PCSA
Side-by-side comparison of Lisata Therapeutics Inc. (LSTA) and Processa Pharmaceuticals Inc. (PCSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LSTA and PCSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LSTA is the larger of the two at $13.1M, about 2.5x PCSA ($5.2M).
- PCSA has been more active in the news (10 items in the past 4 weeks vs 8 for LSTA).
- PCSA has more recent analyst coverage (3 ratings vs 0 for LSTA).
- Company
- Lisata Therapeutics Inc.
- Processa Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $13.1M
- $5.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 8
- 10
- Recent ratings
- 0
- 3
Processa Pharmaceuticals Inc.
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.
Latest LSTA
- SEC Form 10-Q filed by Lisata Therapeutics Inc.
- SEC Form S-3 filed by Lisata Therapeutics Inc.
- SEC Form S-8 filed by Lisata Therapeutics Inc.
- Amendment: Lisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form DEFA14A filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
- SEC Form DEF 14A filed by Lisata Therapeutics Inc.
- SEC Form 3 filed by Lisata Therapeutics Inc.
Latest PCSA
- SEC Form 10-Q filed by Processa Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Processa Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Processa Pharmaceuticals Inc.
- Processa Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Processa Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Processa Pharmaceuticals Announces Key Leadership Appointments
- SEC Form 8-K filed by Processa Pharmaceuticals Inc.
- Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
- SEC Form EFFECT filed by Processa Pharmaceuticals Inc.